tetano
Editor, Senior Moderator
Nat Biotechnol
. 2023 Apr 24.
doi: 10.1038/s41587-023-01774-z. Online ahead of print.
A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines
Aurélien Vander Straeten[SUP] #[/SUP][SUP] 1 [/SUP], Morteza Sarmadi[SUP] #[/SUP][SUP] 1 [/SUP], John L Daristotle[SUP] #[/SUP][SUP] 1 [/SUP], Maria Kanelli[SUP] 1 [/SUP], Lisa H Tostanoski[SUP] 2 [/SUP], Joe Collins[SUP] 1 [/SUP], Apurva Pardeshi[SUP] 1 [/SUP], Jooli Han[SUP] 1 [/SUP], Dhruv Varshney[SUP] 1 [/SUP], Behnaz Eshaghi[SUP] 1 [/SUP], Johnny Garcia[SUP] 1 [/SUP], Timothy A Forster[SUP] 1 [/SUP], Gary Li[SUP] 1 [/SUP], Nandita Menon[SUP] 1 [/SUP], Sydney L Pyon[SUP] 3 [/SUP], Linzixuan Zhang[SUP] 3 [/SUP], Catherine Jacob-Dolan[SUP] 2 4 5 [/SUP], Olivia C Powers[SUP] 2 [/SUP], Kevin Hall[SUP] 2 [/SUP], Shahad K Alsaiari[SUP] 1 [/SUP], Morris Wolf[SUP] 6 [/SUP], Mark W Tibbitt[SUP] 6 [/SUP], Robert Farra, Dan H Barouch[SUP] 2 4 5 [/SUP], Robert Langer[SUP] 7 8 [/SUP], Ana Jaklenec[SUP] 9 [/SUP]
Affiliations
Abstract
Decentralized manufacture of thermostable mRNA vaccines in a microneedle patch (MNP) format could enhance vaccine access in low-resource communities by eliminating the need for a cold chain and trained healthcare personnel. Here we describe an automated process for printing MNP Coronavirus Disease 2019 (COVID-19) mRNA vaccines in a standalone device. The vaccine ink is composed of lipid nanoparticles loaded with mRNA and a dissolvable polymer blend that was optimized for high bioactivity by screening formulations in vitro. We demonstrate that the resulting MNPs are shelf stable for at least 6 months at room temperature when assessed using a model mRNA construct. Vaccine loading efficiency and microneedle dissolution suggest that efficacious, microgram-scale doses of mRNA encapsulated in lipid nanoparticles could be delivered with a single patch. Immunizations in mice using manually produced MNPs with mRNA encoding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain stimulate long-term immune responses similar to those of intramuscular administration.
. 2023 Apr 24.
doi: 10.1038/s41587-023-01774-z. Online ahead of print.
A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines
Aurélien Vander Straeten[SUP] #[/SUP][SUP] 1 [/SUP], Morteza Sarmadi[SUP] #[/SUP][SUP] 1 [/SUP], John L Daristotle[SUP] #[/SUP][SUP] 1 [/SUP], Maria Kanelli[SUP] 1 [/SUP], Lisa H Tostanoski[SUP] 2 [/SUP], Joe Collins[SUP] 1 [/SUP], Apurva Pardeshi[SUP] 1 [/SUP], Jooli Han[SUP] 1 [/SUP], Dhruv Varshney[SUP] 1 [/SUP], Behnaz Eshaghi[SUP] 1 [/SUP], Johnny Garcia[SUP] 1 [/SUP], Timothy A Forster[SUP] 1 [/SUP], Gary Li[SUP] 1 [/SUP], Nandita Menon[SUP] 1 [/SUP], Sydney L Pyon[SUP] 3 [/SUP], Linzixuan Zhang[SUP] 3 [/SUP], Catherine Jacob-Dolan[SUP] 2 4 5 [/SUP], Olivia C Powers[SUP] 2 [/SUP], Kevin Hall[SUP] 2 [/SUP], Shahad K Alsaiari[SUP] 1 [/SUP], Morris Wolf[SUP] 6 [/SUP], Mark W Tibbitt[SUP] 6 [/SUP], Robert Farra, Dan H Barouch[SUP] 2 4 5 [/SUP], Robert Langer[SUP] 7 8 [/SUP], Ana Jaklenec[SUP] 9 [/SUP]
Affiliations
- PMID: 37095347
- DOI: 10.1038/s41587-023-01774-z
Abstract
Decentralized manufacture of thermostable mRNA vaccines in a microneedle patch (MNP) format could enhance vaccine access in low-resource communities by eliminating the need for a cold chain and trained healthcare personnel. Here we describe an automated process for printing MNP Coronavirus Disease 2019 (COVID-19) mRNA vaccines in a standalone device. The vaccine ink is composed of lipid nanoparticles loaded with mRNA and a dissolvable polymer blend that was optimized for high bioactivity by screening formulations in vitro. We demonstrate that the resulting MNPs are shelf stable for at least 6 months at room temperature when assessed using a model mRNA construct. Vaccine loading efficiency and microneedle dissolution suggest that efficacious, microgram-scale doses of mRNA encapsulated in lipid nanoparticles could be delivered with a single patch. Immunizations in mice using manually produced MNPs with mRNA encoding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain stimulate long-term immune responses similar to those of intramuscular administration.